Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: An experimental study
Multidisciplinary Respiratory Medicine · Ocak 2013
YÖKSİS Kayıtları
Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury an experimental study
Multidisciplinary Respiratory Medicine · 2013 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ MUHAMMED YAYLA →
Makale Bilgileri
DergiMultidisciplinary Respiratory Medicine
Yayın TarihiOcak 2013
Cilt / Sayfa8
Scopus ID2-s2.0-84983158147
Erişim🔓 Açık Erişim
Özet
Background: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison. Methods: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered orally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment. Results: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters. Conclusions: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects.
Yazarlar (10)
1
Omer Araz
2
Elif Demirci
3
Elif Yilmazel Ucar
4
Muhammet Calik
5
Didem Pulur
6
Adem Karaman
7
Muhammed Yayla
ORCID: 0000-0002-0659-3084
8
Eren Altun
9
Zekai Halici
10
Metin Akgun
Anahtar Kelimeler
Acute lung injury
Bosentan
Dexamethasone
Kurumlar
Ataturk University, Faculty of Medicine
Erzurum Turkey
Yakutiye Medical Research Center
Erzurum Turkey
Zonguldak Government Hospital
Turkey
Metrikler
21
Atıf
10
Yazar
3
Anahtar Kelime